QBiotics

Brisbane, Australia Founded: 2000 • Age: 26 yrs
Small molecules from plant extracts are developed for medical applications.
Annual revenue - Latest available
Total funding $98.1M 3 rounds
Employees - Tracked headcount
Investors 1 Known backers
Products 3 Services tracked
Competitors 8 Brand Intelligence

About QBiotics

QBiotics is a company based in Brisbane (Australia) founded in 2000 by Victoria Gordon and Paul Reddell. It operates as a HealthTech. QBiotics has raised $98.07 million across 3 funding rounds from investors including TDM Growth Partners. QBiotics offers products and services including Tigilanol Tiglate, EBC-1013, and STELFONTA. QBiotics operates in a competitive market with competitors including Jazz Pharmaceuticals, Zoetis, Ceva, C4 Therapeutics and Erasca, among others.

  • Headquarter Brisbane, Australia
  • Founders Victoria Gordon, Paul Reddell
  • Sectors
    Healthcare
  • Email
    Locked
  • Phone
    Locked
  • Website
    Locked
  • Social
    Locked
  • Legal Name Qbiotics Group
Operational Areas
Healthcare → Veterinary & Animal Health Unlock Sub-Sector Unlock Segment
Healthcare → Medical Devices & Diagnostics Unlock Sub-Sector Unlock Segment
Healthcare → Healthcare Products & Supplies Unlock Sub-Sector Unlock Segment
Key Metrics
  • Annual Revenue
    Not available
  • Net Profit
    Not available
  • EBITDA
    Not available
  • Total Equity Funding
    $98.07 M (USD)

    in 3 rounds

  • Latest Funding Round
    $64.42 M (USD), Series C

    Jun 25, 2021

  • Investors
  • Employee Count
    Not available
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal

Products & Services of QBiotics

QBiotics offers a comprehensive portfolio of products and services, including Tigilanol Tiglate, EBC-1013, and STELFONTA.

Product name locked
Category locked
Primary

Developed as treatment for soft tissue sarcomas oncology.

Product name locked
Category locked
Locked

Designed for treatment of chronic and acute wounds.

Product name locked
Category locked
Locked

Approved for non-resectable mast cell tumors in dogs.

Funding Insights of QBiotics

QBiotics has successfully raised a total of $98.07M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $64.42 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

Investors in QBiotics

QBiotics has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include TDM Growth Partners.

All
Venture Fund
Investor Description Founded Year Domain Location
Growth capital is offered by TDM Growth Partners.
Locked Locked Locked
Premium access

Investor details for QBiotics

Investor domains, locations, round participation, and complete history require an active premium plan.

  • Investor domains
  • Investor locations
  • Funding rounds
  • Participation history

Verified entity values are shown only after access is granted.

Investments & Acquisitions by QBiotics

Investments
Premium access

Investment portfolio details for QBiotics

Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.

  • Portfolio identities
  • Transaction dates
  • Round details
  • Investment values

Verified entity values are shown only after access is granted.

Financial Statements - QBiotics

Premium access

Detailed financials for QBiotics

Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.

  • Historical revenue
  • Profit trends
  • Statement rows
  • Financial ratios

Verified entity values are shown only after access is granted.

Qbiotics Comparisons

QBiotics Primary company
Description
Small molecules from plant extracts are developed for medica...
Location
Brisbane, Australia
Founded Year
2000
Annual Revenue
Not available
Net Profit
Not available
EBITDA
Not available
Employees
Not available
Premium access

Peer comparison for QBiotics

Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.

  • Named peers
  • Headcount comparison
  • Funding comparison
  • Operating benchmarks

Verified entity values are shown only after access is granted.

+
Add Comparison
Available on Premium

Competitors of QBiotics

QBiotics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, Zoetis, Ceva, C4 Therapeutics and Erasca, among others.

Company Name Domain Founded year HQ Location Description
Locked Locked Locked
Novel biopharmaceutical medicines are developed for unmet medical needs.
Locked Locked Locked
Animal medicines, vaccines, and diagnostics are manufactured and supplied.
Locked Locked Locked
Animal health therapeutics are developed and supplied globally by Ceva.
Locked Locked Locked
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
Locked Locked Locked
Small molecule therapeutics for cancer treatment are developed.
Locked Locked Locked
Cancer therapies are developed using selective pathway inhibitors.
Premium access

Detailed competitors of QBiotics

Competitor domains, locations, full profiles, and operating metrics require an active premium plan.

  • Domains and locations
  • Full company profiles
  • Operating metrics
  • Competitive positioning

Verified entity values are shown only after access is granted.

Latest news on Qbiotics

Premium access

Complete news archive for QBiotics

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about QBiotics

QBiotics was founded in 2000 and raised its 1st funding round 16 years after it was founded.

QBiotics is headquartered in Brisbane, Australia. It is registered at Brisbane, Queensland, Australia.

Victoria Gordon is the current CEO of QBiotics. They have also founded this company.

QBiotics is a funded company, having raised a total of $98.07M across 3 funding rounds to date.

QBiotics is engaged in the discovery and development of novel cell signaling small molecules for challenging medical conditions. The company operates in the healthcare sector, specializing in oncology and wound healing solutions. Its lead oncology drug, Tigilanol Tiglate, is in clinical Phase II trials for soft tissue sarcomas and head and neck cancers. Additionally, EBC-1013 is being developed for chronic and acute wounds, with a Phase I trial planned. Veterinary oncology product STELFONTA is commercialized for mast cell tumors in dogs. Innovation is driven by proprietary platforms like EcoLogic and phenotypic screening, leveraging Australias tropical rainforest molecular diversity.

QBiotics's top competitors include Jazz Pharmaceuticals, Zoetis and C4 Therapeutics.

QBiotics offers Tigilanol Tiglate, EBC-1013, and STELFONTA.

QBiotics has 1 investor. Key investors include TDM Growth Partners.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available